# Nebulized Lidocaine and Intranasal Midazolam for NGT Insertion in Children

> **NCT04571879** · PHASE3 · UNKNOWN · sponsor: **Hamad Medical Corporation** · enrollment: 48 (estimated)

## Conditions studied

- Procedural Anxiety
- Procedural Pain

## Interventions

- **DRUG:** Nebulized Lidocaine
- **DRUG:** Intranasal Midazolam
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT04571879
- **Lead sponsor:** Hamad Medical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-25
- **Primary completion:** 2023-12-30
- **Final completion:** 2024-02-28
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04571879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04571879, "Nebulized Lidocaine and Intranasal Midazolam for NGT Insertion in Children". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04571879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*